EVEREST MED

Everest Medicines edged up 0.88% to HK$25.30 today, displaying distinct intraday momentum shifts as the stock opened at HK$25.10, rallied to a session high of HK$25.66 by 10:37 a.m., then retreated to HK$25.10 by 3:01 p.m., suggesting cautious investor sentiment toward the clinical-stage biotech. Q4 financial results highlight the company's growth trajectory: revenues jumped 225% YoY to HK$701M, demonstrating strong commercialization traction, yet the company posted a net loss of HK$26.7M, though YoY loss magnitude narrowed 88%, signaling improving profitability outlook as the pipeline advances. From a valuation standpoint, the stock has tumbled 33.25% year-to-date and trades 67% below its July 2025 peak of HK$77.55, now sitting meaningfully below the 60-day moving average of HK$28. Recent catalysts—LEROCHOL's China NMPA acceptance and the civorebrutinib exclusive licensing agreement with Travere—provide near-term support, though profitability timeline remains a key uncertainty.

Everest Medicines traded with volatility today, dipping to 24.42 HKD in the morning but recovering to close at 25.08 HKD, as the market weighed recent catalysts against profitability concerns. Q4 revenue reached approximately HKD 700 million (up 225.21% year-over-year), supported by a ~USD 1 billion exclusive deal with Travere Therapeutics for Civorebrutinib and China NMPA acceptance of LEROCHOL. However, the company remains loss-making with Q4 net loss of HKD 26.67 million, though improving 87.74% year-over-year. The stock has declined 33.83% year-to-date and sits 67.66% below the 52-week high of 77.55 HKD, trading below the 20-day moving average (26.514 HKD) and 60-day average (28.158 HKD), reflecting market skepticism toward its cash-burn model. While CBC Group's recent purchase of 712,000 shares and BOCOM's Buy rating provide some support, the stock remains in a weakness-correction phase.

Everest Medicines fell 1.5% to HKD 24.82 today, pressured by profit-taking following recent gains and concerns over the commercialization timeline for recent pipeline advances. While Q4 revenue surged to HKD 709 million—a 225% year-over-year increase—the company remains unprofitable, posting a net loss of HKD 26.7 million with a net margin of -3.81%, underscoring the burden of R&D and commercial investments. Recent pipeline momentum includes China NMPA acceptance for renal disease treatment LEROCHOL®, an exclusive licensing agreement with Travere for Civorebrutinib, and a commercialization partnership with Hainan Herui for budesonide enteric capsules; however, these developments will take time to translate into meaningful revenue contributions. Technically, the stock has slumped 68% from its 52-week peak of HKD 77.55 and hovers just 9% above the recent low of HKD 22.70, approaching a near-term floor, while trading notably below its 20-day moving average of HKD 26.51, signaling continued weakness.

Everest Medicines gained 2.2% to HKD 25.2 today, primarily a technical rebound from prior sharp declines. The company reported Q4 operating revenue of HKD 701 million with a striking 225% year-over-year surge, demonstrating accelerating commercialization expansion, though net loss reached HKD 26.7 million with net margin of -3.8%; the loss-shrinkage rate improved 88% versus the prior year quarter, signaling margin compression progress. Stock has fallen 33.51% year-to-date and trades 67.5% below the 52-week high of HKD 77.55, sitting well below the 60-day moving average of HKD 28.65, reflecting market hesitation on profitability inflection timing. Recent product-line advances include an exclusive licensing agreement for BTK inhibitor Civorebrutinib with Travere Therapeutics and China NMPA acceptance of the BLA for LEROCHOL, further strengthening the pipeline in nephrology, anti-infective and immunology domains. However, the company remains loss-making with cash burn sustainability in question, leaving valuation metrics under pressure from profitability outlook uncertainty.

Everest Medicines fell 3.57% to HK$24.66, with morning trading declining 2.98% to HK$24.72 before afternoon losses narrowed to just -0.24%, reflecting profit-taking after prior rallies. The company announced two employee equity award plans today, granting approximately 1.4 million shares collectively, which may trigger dilution concerns. Operationally, Q4 2025 revenues surged 225% year-over-year to HK$701 million, though the company remains unprofitable with net losses of HK$26.7 million—improving 87.74% compared to prior year. From a price perspective, the stock has declined 34.93% year-to-date and now trades 68.2% below its 52-week high of HK$77.55, falling through both the 20-day moving average (HK$26.40) and 60-day moving average (HK$28.83). Positively, the billion-dollar licensing partnership with Travere Therapeutics and LEROCHOL® BLA acceptance in China provide medium-term growth catalysts for its product pipeline.